{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:17:35Z","timestamp":1790371055892,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as autoimmune polyglandular syndrome type 1 (APS-1) is a rare autosomal recessive inborn error of immunity (IEI), which is accompanied by immune dysregulation. Hypoparathyroidism, adrenocortical failure and candidiasis are its typical manifestations. Here we report about recurrent COVID-19 in a 3-year-old boy with APECED, who developed retinopathy with macular atrophy and autoimmune hepatitis after the first episode of SARS-CoV-2 infection. Primary Epstein-Barr virus infection and a new episode of SARS-CoV-2 infection with COVID pneumonia triggered the development of severe hyperinflammation with signs of hemophagocytic lymphohistiocytosis (HLH): progressive cytopenia (thrombocytopenia, anemia, lymphopenia), hypoproteinemia, hypoalbuminemia, high levels of liver enzymes, hyperferritinemia, increased triglycerides levels; and coagulopathy with a low level of fibrinogen. Treatment with corticosteroids and intravenous immunoglobulins did not lead to a significant improvement. The progression of HLH and COVID-pneumonia resulted in a fatal outcome. The rarity and varied presentation of the HLH symptoms led to diagnostic difficulties and diagnosis delay. HLH should be suspected in a patient with immune dysregulation and impaired viral response. Treatment of infection-HLH is a major challenge due to the difficulties in balancing immunosuppression and management of underlying\/triggering infection.<\/jats:p>","DOI":"10.3389\/fped.2023.1086867","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:17:00Z","timestamp":1676553420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Virus-induced hemophagocytic lymphohistiocytosis in a patient with APECED"],"prefix":"10.3389","volume":"11","author":[{"given":"Oksana","family":"Boyarchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olha","family":"Dyvonyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Hariyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Volokha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"B1","first-page":"226","article-title":"APECED Syndrome in childhood: clinical spectrum is enlarging","volume":"68","author":"Valenzise","year":"2016","journal-title":"Minerva Pediatr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.31421","article-title":"APECED-Associated Hepatitis: clinical, biochemical, histological and treatment data from a large, predominantly American cohort","volume":"73","author":"Chascsa","year":"2021","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MCG.0b013e31827356e1","article-title":"Gastrointestinal manifestations in APECED syndrome","volume":"47","author":"Kluger","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"eaav5597","DOI":"10.1126\/scitranslmed.aav5597","article-title":"Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance","volume":"11","author":"Ferre","year":"2019","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"687280","DOI":"10.3389\/fimmu.2021.687280","article-title":"AIRE Gene mutation presenting at age 2 years with autoimmune retinopathy and steroid-responsive acute liver failure: a case report and literature review","volume":"12","author":"Sakaguchi","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/22221751.2022.2090860","article-title":"AIRE Gene mutation predisposing chronic mucocutaneous candidiasis and pigmented retinitis in two kids from a Chinese family","volume":"11","author":"Ma","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.autrev.2017.11.01","article-title":"The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (aps-1)","volume":"17","author":"Guo","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ICU.0000000000000306","article-title":"Ocular manifestations of autoimmune polyendocrinopathy syndrome type 1","volume":"27","author":"Couturier","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/bjophthalmol-2014-305897","article-title":"Retinal degeneration in autoimmune polyglandular syndrome type 1: a case series","volume":"99","author":"Bourgault","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.coi.2021.07.011","article-title":"Infections in the monogenic autoimmune syndrome APECED","volume":"72","author":"Oikonomou","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2008-03-144634","article-title":"Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes","volume":"112","author":"Kisand","year":"2008","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e20210554","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40618-020-01323-4","article-title":"A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in lombardy, Italy: letter to the editor","volume":"43","author":"Beccuti","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"720205","DOI":"10.3389\/fimmu.2021.720205","article-title":"SARS-CoV-2 spike protein-directed monoclonal antibodies may ameliorate COVID-19 complications in APECED patients","volume":"12","author":"Ferr\u00e9","year":"2021","journal-title":"Front Immunol"},{"key":"B15","year":""},{"key":"B16","year":""},{"key":"B17","doi-asserted-by":"publisher","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19","volume":"99","author":"Abers","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1073\/pnas.0809986106","article-title":"Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen","volume":"106","author":"Alimohammadi","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-00571-1","article-title":"Immune cartography of macrophage activation syndrome in the COVID-19 era","volume":"17","author":"McGonagle","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the north American consortium for histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.crohns.2012.05.002","article-title":"A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn's Disease patient on azathioprine, successfully treated with rituximab","volume":"7","author":"Fitzgerald","year":"2013","journal-title":"J Crohns Colitis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e26264","DOI":"10.1002\/pbc.26264","article-title":"Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study","volume":"64","author":"Xu","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2014.121608","article-title":"The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis","volume":"100","author":"Bode","year":"2015","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","volume":"22","author":"Henderson","year":"2020","journal-title":"Paediatr Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American college of rheumatology\/paediatric rheumatology international trials organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2020006216","article-title":"Tocilizumab not associated with increased infection risk after CAR T-cell therapy:\u00a0implications for COVID-19?","volume":"136","author":"Frigault","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/bjh.12386","article-title":"Treatment of epstein barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemoimmunotherapeutic regimens","volume":"162","author":"Chellapandian","year":"2013","journal-title":"Br J Haematol"},{"key":"B30","first-page":"124","article-title":"Awareness of primary immunodeficiency diseases among medical students","volume":"285","author":"Boyarchuk","year":"2018","journal-title":"Georgian Med News"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.31688\/ABMU.2019.54.1.18","article-title":"Evaluation of knowledge about primary immunodeficiencies among postgraduate medical students","volume":"54","author":"Boyarchuk","year":"2019","journal-title":"Arch Balk Med Union"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1086867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:17:03Z","timestamp":1676553423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1086867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":31,"alternative-id":["10.3389\/fped.2023.1086867"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1086867","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"1086867"}}